View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMaxCyte 将来の成長Future 基準チェック /26MaxCyteは、2.5%と24.2%でそれぞれ年率2.5%で利益と収益が成長すると予測される一方、EPSはgrowで4.2%年率。主要情報2.5%収益成長率4.25%EPS成長率Life Sciences 収益成長57.0%収益成長率24.2%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日25 Jun 2025今後の成長に関する最新情報お知らせ • May 08MaxCyte, Inc. Reiterates Revenue Guidance for the Year 2025MaxCyte, Inc. reiterated revenue guidance for the year 2025. For the year, the company reiterates core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.お知らせ • Mar 12MaxCyte, Inc. Provides Revenue Guidance for the Year 2025MaxCyte, Inc. provided revenue guidance for the year 2025. For the period, the company expects core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.お知らせ • Dec 10MaxCyte, Inc. Raises Revenue Guidance for 2024MaxCyte, Inc. raised Revenue guidance for 2024. For the period, the company expects core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.お知らせ • Nov 07MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024MaxCyte, Inc. updated revenue guidance for the full year 2024. For the period, Company expects core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.分析記事 • Aug 09MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAs you might know, MaxCyte, Inc. ( LON:MXCT ) just kicked off its latest second-quarter results with some very strong...お知らせ • Aug 07MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. reaffirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance. The company continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.すべての更新を表示Recent updatesお知らせ • Jun 25MaxCyte Shareholders Approves Common Stock Cancelation DateMaxCyte, Inc. provided further update with regards to the cancellation of admission of the Company's common stock ("Common Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at the Annual General Meeting held on 18 June 2025. Shareholders are reminded that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025. Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.お知らせ • May 08MaxCyte, Inc. Reiterates Revenue Guidance for the Year 2025MaxCyte, Inc. reiterated revenue guidance for the year 2025. For the year, the company reiterates core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.お知らせ • Apr 17MaxCyte, Inc., Annual General Meeting, Jun 18, 2025MaxCyte, Inc., Annual General Meeting, Jun 18, 2025. Location: 9713 key west avenue, suite 400, rockville, 20850, maryland United Statesお知らせ • Apr 10MaxCyte, Inc. to Report Q1, 2025 Results on May 07, 2025MaxCyte, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025新しいナラティブ • Mar 27SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects Acquisition of SeQure Dx and SPL portfolio expansion could drive future revenue growth through improved offerings and new clinical progressions. Reported Earnings • Mar 12Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.39 loss per share (further deteriorated from US$0.37 loss in FY 2023). Revenue: US$38.6m (down 6.4% from FY 2023). Net loss: US$41.1m (loss widened 8.3% from FY 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.1%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Mar 12MaxCyte, Inc. Provides Revenue Guidance for the Year 2025MaxCyte, Inc. provided revenue guidance for the year 2025. For the period, the company expects core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.分析記事 • Feb 28MaxCyte, Inc.'s (LON:MXCT) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of InvestorsMaxCyte, Inc. ( LON:MXCT ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The...お知らせ • Feb 07MaxCyte, Inc. to Report Q4, 2024 Results on Mar 11, 2025MaxCyte, Inc. announced that they will report Q4, 2024 results at 4:30 PM, GMT Standard Time on Mar 11, 2025お知らせ • Jan 30MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million.MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million on January 30, 2025. Maxcyte paid a total consideration of $4.5 million at closing in cash for the entire issued share capital of SeQure DX on a cash free, debt free basis using Maxcyte’s existing cash resources and an additional amount of $2.5 million to be paid in contingent consideration if the SeQure exceeds certain revenue targets. For the period ending December 31, 2024, SeQure Dx, Inc. reported total revenue of $1.7 million and net loss of $6.5 million and total assets of $0.7 million. MaxCyte, Inc. (AIM:MXCT) completed the acquisition of SeQure Dx, Inc. on January 30, 2025.分析記事 • Jan 29Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65?MaxCyte, Inc. ( LON:MXCT ), might not be a large cap stock, but it led the AIM gainers with a relatively large price...Buy Or Sell Opportunity • Jan 24Now 24% undervaluedOver the last 90 days, the stock has risen 31% to UK£3.82. The fair value is estimated to be UK£5.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.New Risk • Jan 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$30m net loss in 2 years). Share price has been volatile over the past 3 months (7.2% average weekly change).分析記事 • Jan 07We're Not Very Worried About MaxCyte's (LON:MXCT) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...お知らせ • Dec 23MaxCyte, Inc. Announces Retirement of Board Member Art MandellMaxCyte, Inc. announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors. During Mr. Mandell’s tenure, MaxCyte has achieved significant milestones including its initial public offering on the UK AIM exchange and US Nasdaq Listing, the launch of its flagship ExPERT™ platform, signing 29 Strategic Platform Licenses with cell and gene therapy biotech companies and supporting the industry’s first, FDA-approved, CRISPR edited non-viral cell therapy.分析記事 • Dec 10Getting In Cheap On MaxCyte, Inc. (LON:MXCT) Might Be DifficultWhen close to half the companies in the Life Sciences industry in the United Kingdom have price-to-sales ratios (or...お知らせ • Dec 10MaxCyte, Inc. Raises Revenue Guidance for 2024MaxCyte, Inc. raised Revenue guidance for 2024. For the period, the company expects core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.Reported Earnings • Nov 07Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.11 loss per share (further deteriorated from US$0.11 loss in 3Q 2023). Revenue: US$8.16m (up 2.0% from 3Q 2023). Net loss: US$11.6m (loss widened 2.7% from 3Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 07MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024MaxCyte, Inc. updated revenue guidance for the full year 2024. For the period, Company expects core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.お知らせ • Oct 15MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive DirectorMaxCyte, Inc. announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. Ms. Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as Chief Executive Officer of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene modified therapy. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc., Chief Executive Officer/General Manager of General Electric Healthcare's Cell Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy company. Currently, Ms. Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics, Certara, DermTech, Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines. Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business. Cynthia Collins, was previously appointed as an independent director to the Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the District of Delaware approved the sale of a substantial amount of DermTech Inc.'s assets through a court-supervised auction.お知らせ • Oct 11MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024MaxCyte, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024お知らせ • Oct 10MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial OfficerMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company’s market impact in Cell and Gene Therapy. Prior to his role as Chief Commercial Officer, Mr. Soleymannezhad was the Executive Vice President of Bioprocessing, where he led global product development and marketing strategy for MaxCyte’s bioprocessing business. Mr. Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to Executive Vice President of Bioprocessing at MaxCyte, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience and oversaw a team of 140 employees across four global manufacturing, development, and commercial sites. Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing-Americas at Tosoh and served on the board of Semba Biosciences.Recent Insider Transactions Derivative • Oct 04Independent Non-Executive Director exercised options and sold UK£133k worth of stockOn the 2nd of October, Stanley Erck exercised 48k options at a strike price of around UK£0.03 and sold these shares for an average price of UK£2.83 per share. This trade did not impact their existing holding. Since June 2024, Stanley has owned 247.75k shares directly. Company insiders have collectively sold UK£760k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Sep 05Independent Non-Executive Director notifies of intention to sell stockStanley Erck intends to sell 143k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of September. If the sale is conducted around the recent share price of UK£3.30, it would amount to UK£472k. Since June 2024, Stanley has owned 247.75k shares directly. Company insiders have collectively sold UK£481k more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Aug 09MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAs you might know, MaxCyte, Inc. ( LON:MXCT ) just kicked off its latest second-quarter results with some very strong...Reported Earnings • Aug 07Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.09 loss per share (improved from US$0.10 loss in 2Q 2023). Revenue: US$10.4m (up 15% from 2Q 2023). Net loss: US$9.38m (loss narrowed 11% from 2Q 2023). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 07MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. reaffirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance. The company continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.お知らせ • Jul 10MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024MaxCyte, Inc. announced that they will report Q2, 2024 results at 4:30 PM, GMT Standard Time on Aug 06, 2024お知らせ • Jul 03MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth IndexMaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth IndexRecent Insider Transactions Derivative • Jun 23Insider notifies of intention to sell stockThomas Ross intends to sell 133k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of June. If the sale is conducted around the recent share price of UK£3.48, it would amount to UK£464k. As of today, Thomas currently holds no shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold UK£447k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Jun 13President recently bought UK£384k worth of stockOn the 10th of June, Maher Masoud bought around 100k shares on-market at roughly UK£3.84 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Maher's only on-market trade for the last 12 months.分析記事 • May 30Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%MaxCyte, Inc. ( LON:MXCT ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • May 10Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest ResultsA week ago, MaxCyte, Inc. ( LON:MXCT ) came out with a strong set of first-quarter numbers that could potentially lead...New Risk • May 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.07% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$41m net loss in 2 years).お知らせ • May 09Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. affirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and is increasing SPL Program-related revenue guidance. MaxCyte continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $5 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY™.Reported Earnings • May 08First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: US$0.092 loss per share (improved from US$0.11 loss in 1Q 2023). Revenue: US$11.3m (up 32% from 1Q 2023). Net loss: US$9.53m (loss narrowed 13% from 1Q 2023). Revenue exceeded analyst estimates by 51%. Earnings per share (EPS) also surpassed analyst estimates by 28%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 28MaxCyte, Inc., Annual General Meeting, Jun 11, 2024MaxCyte, Inc., Annual General Meeting, Jun 11, 2024, at 11:00 US Eastern Standard Time. Location: 9713 Key West Avenue, Suite 400 Rockville Maryland United States Agenda: To elect the Board’s three nominees as identified in the accompanying Proxy Statement as Class III directors: Will Brooke, John Johnston, and Richard Douglas; to approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the shares of the Company’s common stock issuable thereunder by 2,300,000 shares; to ratify the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.お知らせ • Apr 11MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024MaxCyte, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024Major Estimate Revision • Mar 19Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$39.5m to US$34.5m. Forecast losses increased from -US$0.43 to -US$0.483 per share. Life Sciences industry in the United Kingdom expected to see average net income decline 35% next year. Consensus price target broadly unchanged at UK£7.64. Share price rose 4.0% to UK£3.28 over the past week.お知らせ • Mar 14MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024MaxCyte, Inc. reiterated earnings guidance for the year 2024. Management is reiterating 2024 revenue guidance for core business revenue and SPL Program-related revenue. Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million. Outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM and reflects a difficult year-over-year comparison from a client milestone recognized in 2023 that was initially expected in 2024.分析記事 • Mar 14Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near TermMarket forces rained on the parade of MaxCyte, Inc. ( LON:MXCT ) shareholders today, when the analysts downgraded their...Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.37 loss per share (further deteriorated from US$0.23 loss in FY 2022). Revenue: US$41.3m (down 6.7% from FY 2022). Net loss: US$37.9m (loss widened 61% from FY 2022). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year whereas the company’s share price has fallen by 30% per year.お知らせ • Mar 07MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024MaxCyte, Inc. provided revenue guidance for the fiscal year 2023 and 2024. For the year 2023, Company re-affirms total revenue to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022. Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.For the Year 2024, Company expects Core revenue to be flat to 5% growth compared to 2023.分析記事 • Mar 07Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Feb 10MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024MaxCyte, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024お知らせ • Jan 27MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific OfficerMaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.’s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company’s Scientific Advisory Board.お知らせ • Jan 09MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023MaxCyte, Inc. provided preliminary financial guidance for the fourth quarter and full year ended December 31, 2023. Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.お知らせ • Dec 12MaxCyte, Inc. Provides Revenue Guidance Update for 2023MaxCyte, Inc. is reiterating 2023 expected core business revenue of $28 million- $30 million, and the company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million. Core business revenue consists of sales and leases of instrument and disposables to cell therapy and drug discovery customers and excludes any milestone revenues under SPL programs.Recent Insider Transactions Derivative • Dec 03Founder exercised options and sold UK£100k worth of stockOn the 1st of December, Douglas Doerfler exercised 26k options at a strike price of around UK£0.032 and sold these shares for an average price of UK£3.94 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Nov 18Independent Non-Executive Director notifies of intention to sell stockJohn Johnston intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of November. If the sale is conducted around the recent share price of UK£2.97, it would amount to UK£59k. Since March 2023, John has owned 120.58k shares directly. Company insiders have collectively sold UK£1.4m more than they bought, via options and on-market transactions in the last 12 months.New Risk • Nov 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$42m net loss in 2 years). Share price has been volatile over the past 3 months (7.9% average weekly change).お知らせ • Nov 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the period, the company expects total revenue to be approximately $34 million - 36 million.Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.063 loss in 3Q 2022). Revenue: US$8.00m (down 25% from 3Q 2022). Net loss: US$11.3m (loss widened 75% from 3Q 2022). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 7.8%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years). Share price has been volatile over the past 3 months (7.5% average weekly change).お知らせ • Oct 07MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023MaxCyte, Inc. provided revenue guidance for the third quarter and full year of 2023. Total revenue of $7.8 million to $8.0 million in the third quarter of 2023, a decrease of 25% to 27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector.For the full year, the company’s total revenue now expected to be approximately $34 million to $36 million.分析記事 • Oct 07Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%Market forces rained on the parade of MaxCyte, Inc. ( LON:MXCT ) shareholders today, when the analysts downgraded their...Major Estimate Revision • Oct 06Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$45.0m to US$34.9m. Forecast losses increased from -US$0.348 to -US$0.358 per share. Life Sciences industry in the United Kingdom expected to see average net income decline 0.1% next year. Consensus price target down from UK£7.68 to UK£6.88. Share price fell 18% to UK£2.10 over the past week.お知らせ • Oct 05MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023MaxCyte, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023お知らせ • Sep 07Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. Mr. Soleymannezhad will lead global product development and marketing strategy for MaxCyte's bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and manufacturing using transient expression to produce complex proteins, vaccines and biologics at scale. Mr. Soleymannezhad brings almost 20 years of technical, sales and marketing expertise in biomanufacturing, bioprocessing and bioanalysis to his new role. Most recently, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience overseeing a team of 140 employees across four global manufacturing, development, and commercial sites. During his tenure at Tosoh, Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing Americas and served on the board of Semba Biosciences. Mr. Soleymannezhad received a Master of Business Administration in finance from Jones Graduate School of Business at Rice University in Texas after completing his Master and Bachelor of Chemical Engineering at University of Western Ontario's Faculty of Engineering in Canada.New Risk • Aug 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years).分析記事 • Aug 12Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Aug 10Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: US$0.10 loss per share (further deteriorated from US$0.081 loss in 2Q 2022). Revenue: US$9.04m (down 5.9% from 2Q 2022). Net loss: US$10.5m (loss widened 27% from 2Q 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 4.2%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Aug 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects core revenue to be comparable to 2022 and Strategic Platform License program-related revenue expectations remain unchanged at approximately $6 million.お知らせ • Jul 14MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023MaxCyte, Inc. announced that they will report Q2, 2023 results at 4:30 PM, GMT Standard Time on Aug 09, 2023Recent Insider Transactions Derivative • Jul 13Founder notifies of intention to sell stockDouglas Doerfler intends to sell 90k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of July. If the sale is conducted around the recent share price of UK£3.61, it would amount to UK£325k. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jun 29Independent Non-Executive Director notifies of intention to sell stockJohn Johnston intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of June. If the sale is conducted around the recent share price of UK£3.68, it would amount to UK£92k. Since March 2023, John has owned 120.58k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jun 17Founder exercised options and sold UK£173k worth of stockOn the 14th of June, Douglas Doerfler exercised 44k options at a strike price of around UK£0.032 and sold these shares for an average price of UK£3.97 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • May 17Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$54.2m to US$48.3m. Forecast losses increased from -US$0.322 to -US$0.33 per share. Life Sciences industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target down from UK£9.67 to UK£8.52. Share price fell 20% to UK£3.05 over the past week.分析記事 • May 15MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%Market forces rained on the parade of MaxCyte, Inc. ( LON:MXCT ) shareholders today, when the analysts downgraded their...分析記事 • May 14Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%The MaxCyte, Inc. ( LON:MXCT ) share price has fared very poorly over the last month, falling by a substantial 28%. The...Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.04 loss in 1Q 2022). Revenue: US$8.58m (down 26% from 1Q 2022). Net loss: US$10.9m (loss widened 168% from 1Q 2022). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.お知らせ • May 11MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects total revenue to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and Strategic Platform License (“SPL”) program-related revenue expectations remaining the same at approximately $6 million for the year.分析記事 • Apr 27We Think MaxCyte (LON:MXCT) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Board Change • Apr 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Member of Scientific Advisory Board Marcela Maus was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Apr 01Key Executive recently bought UK£280k worth of stockOn the 29th of March, Richard Douglas bought around 80k shares on-market at roughly UK£3.51 per share. This transaction increased Richard's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.Reported Earnings • Mar 16Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)Full year 2022 results: US$0.23 loss per share (further deteriorated from US$0.21 loss in FY 2021). Revenue: US$44.3m (up 31% from FY 2021). Net loss: US$23.6m (loss widened 24% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings.Recent Insider Transactions Derivative • Feb 05Founder exercised options and sold UK£139k worth of stockOn the 2nd of February, Douglas Doerfler exercised 30k options at a strike price of around UK£0.033 and sold these shares for an average price of UK£4.66 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£996k more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Feb 02MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023MaxCyte, Inc. announced that they will report Q4, 2022 results at 4:30 PM, GMT Standard Time on Mar 15, 2023Recent Insider Transactions Derivative • Jan 07Founder exercised options and sold UK£127k worth of stockOn the 5th of January, Douglas Doerfler exercised 30k options at a strike price of around UK£0.034 and sold these shares for an average price of UK£4.27 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£642k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Dec 07Insider exercised options and sold UK£113k worth of stockOn the 5th of December, Thomas Ross exercised 29k options at a strike price of around UK£0.89 and sold these shares for an average price of UK£4.77 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£415k more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Nov 20Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$0.29 to -US$0.26 per share. Revenue forecast steady at US$44.7m. Life Sciences industry in the United Kingdom expected to see average net income growth of 24% next year. Consensus price target broadly unchanged at UK£10.12. Share price rose 3.5% to UK£5.85 over the past week.Recent Insider Transactions Derivative • Nov 04Insider exercised options and sold UK£154k worth of stockOn the 2nd of November, Thomas Ross exercised 29k options at a strike price of around UK£0.73 and sold these shares for an average price of UK£6.03 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£6.8m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Oct 13Insider exercised options and sold UK£147k worth of stockOn the 11th of October, Thomas Ross exercised 29k options at a strike price of around UK£0.76 and sold these shares for an average price of UK£5.81 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£6.6m more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$43.6m to US$44.7m. Forecast EPS reduced from -US$0.25 to -US$0.28 per share. Life Sciences industry in the United Kingdom expected to see average net income growth of 24% next year. Consensus price target up from UK£9.76 to UK£10.18. Share price rose 6.2% to UK£4.73 over the past week.Reported Earnings • Aug 11Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.081 loss per share (down from US$0.052 loss in 2Q 2021). Revenue: US$9.61m (up 35% from 2Q 2021). Net loss: US$8.26m (loss widened 87% from 2Q 2021). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 25% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.04 loss per share (up from US$0.088 loss in 1Q 2021). Revenue: US$11.6m (up 78% from 1Q 2021). Net loss: US$4.07m (loss narrowed 43% from 1Q 2021). Revenue exceeded analyst estimates by 36%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Over the next year, revenue is forecast to grow 17%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.業績と収益の成長予測AIM:MXCT - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202764N/A-15N/A212/31/202650-40-28N/A612/31/202541-41-31N/A63/31/202538-42-33-31N/A12/31/202439-41-29-28N/A9/30/202446-36-21-19N/A6/30/202445-35-25-23N/A3/31/202444-37-31-28N/A12/31/202341-38-25-22N/A9/30/202338-37-34-29N/A6/30/202341-33-34-26N/A3/31/202341-30-29-15N/A12/31/202244-24-33-15N/A9/30/202242-24-27-10N/A6/30/202241-20-20-4N/A3/31/202239-16-19-10N/A12/31/202134-19-15-11N/A9/30/202132-17-15-12N/A6/30/202129-17-14-12N/A3/31/202127-16-10-8N/A12/31/202026-12-11-9N/A9/30/202024-11-10-8N/A6/30/202024-9-10-8N/A3/31/202023-11-13-11N/A12/31/201922-13-10-9N/A9/30/201920-13-11-10N/A6/30/201918-14-11-10N/A3/31/201917-11-11-10N/A12/31/201817-9N/A-10N/A9/30/201816-10N/A-11N/A6/30/201815-10N/A-11N/A3/31/201814-10N/A-10N/A12/31/201714-10N/A-10N/A9/30/201713-8N/A-8N/A6/30/201713-6N/A-6N/A3/31/201713-5N/A-4N/A12/31/201612-4N/A-2N/A9/30/201611-4N/A-2N/A6/30/201611-3N/A-2N/A3/31/201610-3N/A-1N/A12/31/20159-4N/A0N/A9/30/20159-4N/A0N/A6/30/20158-4N/A0N/A3/31/20158-4N/A-1N/A12/31/20147-4N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MXCT今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: MXCT今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: MXCT今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: MXCTの収益 ( 24.2% ) UK市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: MXCTの収益 ( 24.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MXCTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/06/27 12:15終値2025/06/25 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MaxCyte, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Mark MassaroBTIGMatthew HewittCraig-Hallum Capital Group LLCJulie SimmondsPanmure Liberum6 その他のアナリストを表示
お知らせ • May 08MaxCyte, Inc. Reiterates Revenue Guidance for the Year 2025MaxCyte, Inc. reiterated revenue guidance for the year 2025. For the year, the company reiterates core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
お知らせ • Mar 12MaxCyte, Inc. Provides Revenue Guidance for the Year 2025MaxCyte, Inc. provided revenue guidance for the year 2025. For the period, the company expects core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
お知らせ • Dec 10MaxCyte, Inc. Raises Revenue Guidance for 2024MaxCyte, Inc. raised Revenue guidance for 2024. For the period, the company expects core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.
お知らせ • Nov 07MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024MaxCyte, Inc. updated revenue guidance for the full year 2024. For the period, Company expects core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.
分析記事 • Aug 09MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAs you might know, MaxCyte, Inc. ( LON:MXCT ) just kicked off its latest second-quarter results with some very strong...
お知らせ • Aug 07MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. reaffirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance. The company continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.
お知らせ • Jun 25MaxCyte Shareholders Approves Common Stock Cancelation DateMaxCyte, Inc. provided further update with regards to the cancellation of admission of the Company's common stock ("Common Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at the Annual General Meeting held on 18 June 2025. Shareholders are reminded that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025. Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.
お知らせ • May 08MaxCyte, Inc. Reiterates Revenue Guidance for the Year 2025MaxCyte, Inc. reiterated revenue guidance for the year 2025. For the year, the company reiterates core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
お知らせ • Apr 17MaxCyte, Inc., Annual General Meeting, Jun 18, 2025MaxCyte, Inc., Annual General Meeting, Jun 18, 2025. Location: 9713 key west avenue, suite 400, rockville, 20850, maryland United States
お知らせ • Apr 10MaxCyte, Inc. to Report Q1, 2025 Results on May 07, 2025MaxCyte, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
新しいナラティブ • Mar 27SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects Acquisition of SeQure Dx and SPL portfolio expansion could drive future revenue growth through improved offerings and new clinical progressions.
Reported Earnings • Mar 12Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.39 loss per share (further deteriorated from US$0.37 loss in FY 2023). Revenue: US$38.6m (down 6.4% from FY 2023). Net loss: US$41.1m (loss widened 8.3% from FY 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.1%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 12MaxCyte, Inc. Provides Revenue Guidance for the Year 2025MaxCyte, Inc. provided revenue guidance for the year 2025. For the period, the company expects core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
分析記事 • Feb 28MaxCyte, Inc.'s (LON:MXCT) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of InvestorsMaxCyte, Inc. ( LON:MXCT ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The...
お知らせ • Feb 07MaxCyte, Inc. to Report Q4, 2024 Results on Mar 11, 2025MaxCyte, Inc. announced that they will report Q4, 2024 results at 4:30 PM, GMT Standard Time on Mar 11, 2025
お知らせ • Jan 30MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million.MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million on January 30, 2025. Maxcyte paid a total consideration of $4.5 million at closing in cash for the entire issued share capital of SeQure DX on a cash free, debt free basis using Maxcyte’s existing cash resources and an additional amount of $2.5 million to be paid in contingent consideration if the SeQure exceeds certain revenue targets. For the period ending December 31, 2024, SeQure Dx, Inc. reported total revenue of $1.7 million and net loss of $6.5 million and total assets of $0.7 million. MaxCyte, Inc. (AIM:MXCT) completed the acquisition of SeQure Dx, Inc. on January 30, 2025.
分析記事 • Jan 29Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65?MaxCyte, Inc. ( LON:MXCT ), might not be a large cap stock, but it led the AIM gainers with a relatively large price...
Buy Or Sell Opportunity • Jan 24Now 24% undervaluedOver the last 90 days, the stock has risen 31% to UK£3.82. The fair value is estimated to be UK£5.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.
New Risk • Jan 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$30m net loss in 2 years). Share price has been volatile over the past 3 months (7.2% average weekly change).
分析記事 • Jan 07We're Not Very Worried About MaxCyte's (LON:MXCT) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...
お知らせ • Dec 23MaxCyte, Inc. Announces Retirement of Board Member Art MandellMaxCyte, Inc. announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors. During Mr. Mandell’s tenure, MaxCyte has achieved significant milestones including its initial public offering on the UK AIM exchange and US Nasdaq Listing, the launch of its flagship ExPERT™ platform, signing 29 Strategic Platform Licenses with cell and gene therapy biotech companies and supporting the industry’s first, FDA-approved, CRISPR edited non-viral cell therapy.
分析記事 • Dec 10Getting In Cheap On MaxCyte, Inc. (LON:MXCT) Might Be DifficultWhen close to half the companies in the Life Sciences industry in the United Kingdom have price-to-sales ratios (or...
お知らせ • Dec 10MaxCyte, Inc. Raises Revenue Guidance for 2024MaxCyte, Inc. raised Revenue guidance for 2024. For the period, the company expects core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.
Reported Earnings • Nov 07Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.11 loss per share (further deteriorated from US$0.11 loss in 3Q 2023). Revenue: US$8.16m (up 2.0% from 3Q 2023). Net loss: US$11.6m (loss widened 2.7% from 3Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 07MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024MaxCyte, Inc. updated revenue guidance for the full year 2024. For the period, Company expects core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.
お知らせ • Oct 15MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive DirectorMaxCyte, Inc. announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. Ms. Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as Chief Executive Officer of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene modified therapy. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc., Chief Executive Officer/General Manager of General Electric Healthcare's Cell Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy company. Currently, Ms. Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics, Certara, DermTech, Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines. Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business. Cynthia Collins, was previously appointed as an independent director to the Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the District of Delaware approved the sale of a substantial amount of DermTech Inc.'s assets through a court-supervised auction.
お知らせ • Oct 11MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024MaxCyte, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
お知らせ • Oct 10MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial OfficerMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company’s market impact in Cell and Gene Therapy. Prior to his role as Chief Commercial Officer, Mr. Soleymannezhad was the Executive Vice President of Bioprocessing, where he led global product development and marketing strategy for MaxCyte’s bioprocessing business. Mr. Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to Executive Vice President of Bioprocessing at MaxCyte, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience and oversaw a team of 140 employees across four global manufacturing, development, and commercial sites. Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing-Americas at Tosoh and served on the board of Semba Biosciences.
Recent Insider Transactions Derivative • Oct 04Independent Non-Executive Director exercised options and sold UK£133k worth of stockOn the 2nd of October, Stanley Erck exercised 48k options at a strike price of around UK£0.03 and sold these shares for an average price of UK£2.83 per share. This trade did not impact their existing holding. Since June 2024, Stanley has owned 247.75k shares directly. Company insiders have collectively sold UK£760k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Sep 05Independent Non-Executive Director notifies of intention to sell stockStanley Erck intends to sell 143k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of September. If the sale is conducted around the recent share price of UK£3.30, it would amount to UK£472k. Since June 2024, Stanley has owned 247.75k shares directly. Company insiders have collectively sold UK£481k more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Aug 09MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAs you might know, MaxCyte, Inc. ( LON:MXCT ) just kicked off its latest second-quarter results with some very strong...
Reported Earnings • Aug 07Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.09 loss per share (improved from US$0.10 loss in 2Q 2023). Revenue: US$10.4m (up 15% from 2Q 2023). Net loss: US$9.38m (loss narrowed 11% from 2Q 2023). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 07MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. reaffirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance. The company continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.
お知らせ • Jul 10MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024MaxCyte, Inc. announced that they will report Q2, 2024 results at 4:30 PM, GMT Standard Time on Aug 06, 2024
お知らせ • Jul 03MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth IndexMaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index
Recent Insider Transactions Derivative • Jun 23Insider notifies of intention to sell stockThomas Ross intends to sell 133k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of June. If the sale is conducted around the recent share price of UK£3.48, it would amount to UK£464k. As of today, Thomas currently holds no shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold UK£447k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Jun 13President recently bought UK£384k worth of stockOn the 10th of June, Maher Masoud bought around 100k shares on-market at roughly UK£3.84 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Maher's only on-market trade for the last 12 months.
分析記事 • May 30Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%MaxCyte, Inc. ( LON:MXCT ) shareholders would be excited to see that the share price has had a great month, posting a...
分析記事 • May 10Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest ResultsA week ago, MaxCyte, Inc. ( LON:MXCT ) came out with a strong set of first-quarter numbers that could potentially lead...
New Risk • May 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.07% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$41m net loss in 2 years).
お知らせ • May 09Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. affirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and is increasing SPL Program-related revenue guidance. MaxCyte continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $5 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY™.
Reported Earnings • May 08First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: US$0.092 loss per share (improved from US$0.11 loss in 1Q 2023). Revenue: US$11.3m (up 32% from 1Q 2023). Net loss: US$9.53m (loss narrowed 13% from 1Q 2023). Revenue exceeded analyst estimates by 51%. Earnings per share (EPS) also surpassed analyst estimates by 28%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 28MaxCyte, Inc., Annual General Meeting, Jun 11, 2024MaxCyte, Inc., Annual General Meeting, Jun 11, 2024, at 11:00 US Eastern Standard Time. Location: 9713 Key West Avenue, Suite 400 Rockville Maryland United States Agenda: To elect the Board’s three nominees as identified in the accompanying Proxy Statement as Class III directors: Will Brooke, John Johnston, and Richard Douglas; to approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the shares of the Company’s common stock issuable thereunder by 2,300,000 shares; to ratify the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.
お知らせ • Apr 11MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024MaxCyte, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
Major Estimate Revision • Mar 19Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$39.5m to US$34.5m. Forecast losses increased from -US$0.43 to -US$0.483 per share. Life Sciences industry in the United Kingdom expected to see average net income decline 35% next year. Consensus price target broadly unchanged at UK£7.64. Share price rose 4.0% to UK£3.28 over the past week.
お知らせ • Mar 14MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024MaxCyte, Inc. reiterated earnings guidance for the year 2024. Management is reiterating 2024 revenue guidance for core business revenue and SPL Program-related revenue. Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million. Outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM and reflects a difficult year-over-year comparison from a client milestone recognized in 2023 that was initially expected in 2024.
分析記事 • Mar 14Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near TermMarket forces rained on the parade of MaxCyte, Inc. ( LON:MXCT ) shareholders today, when the analysts downgraded their...
Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.37 loss per share (further deteriorated from US$0.23 loss in FY 2022). Revenue: US$41.3m (down 6.7% from FY 2022). Net loss: US$37.9m (loss widened 61% from FY 2022). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year whereas the company’s share price has fallen by 30% per year.
お知らせ • Mar 07MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024MaxCyte, Inc. provided revenue guidance for the fiscal year 2023 and 2024. For the year 2023, Company re-affirms total revenue to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022. Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.For the Year 2024, Company expects Core revenue to be flat to 5% growth compared to 2023.
分析記事 • Mar 07Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Feb 10MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024MaxCyte, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024
お知らせ • Jan 27MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific OfficerMaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.’s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company’s Scientific Advisory Board.
お知らせ • Jan 09MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023MaxCyte, Inc. provided preliminary financial guidance for the fourth quarter and full year ended December 31, 2023. Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.
お知らせ • Dec 12MaxCyte, Inc. Provides Revenue Guidance Update for 2023MaxCyte, Inc. is reiterating 2023 expected core business revenue of $28 million- $30 million, and the company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million. Core business revenue consists of sales and leases of instrument and disposables to cell therapy and drug discovery customers and excludes any milestone revenues under SPL programs.
Recent Insider Transactions Derivative • Dec 03Founder exercised options and sold UK£100k worth of stockOn the 1st of December, Douglas Doerfler exercised 26k options at a strike price of around UK£0.032 and sold these shares for an average price of UK£3.94 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Nov 18Independent Non-Executive Director notifies of intention to sell stockJohn Johnston intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of November. If the sale is conducted around the recent share price of UK£2.97, it would amount to UK£59k. Since March 2023, John has owned 120.58k shares directly. Company insiders have collectively sold UK£1.4m more than they bought, via options and on-market transactions in the last 12 months.
New Risk • Nov 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$42m net loss in 2 years). Share price has been volatile over the past 3 months (7.9% average weekly change).
お知らせ • Nov 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the period, the company expects total revenue to be approximately $34 million - 36 million.
Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.063 loss in 3Q 2022). Revenue: US$8.00m (down 25% from 3Q 2022). Net loss: US$11.3m (loss widened 75% from 3Q 2022). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 7.8%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years). Share price has been volatile over the past 3 months (7.5% average weekly change).
お知らせ • Oct 07MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023MaxCyte, Inc. provided revenue guidance for the third quarter and full year of 2023. Total revenue of $7.8 million to $8.0 million in the third quarter of 2023, a decrease of 25% to 27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector.For the full year, the company’s total revenue now expected to be approximately $34 million to $36 million.
分析記事 • Oct 07Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%Market forces rained on the parade of MaxCyte, Inc. ( LON:MXCT ) shareholders today, when the analysts downgraded their...
Major Estimate Revision • Oct 06Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$45.0m to US$34.9m. Forecast losses increased from -US$0.348 to -US$0.358 per share. Life Sciences industry in the United Kingdom expected to see average net income decline 0.1% next year. Consensus price target down from UK£7.68 to UK£6.88. Share price fell 18% to UK£2.10 over the past week.
お知らせ • Oct 05MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023MaxCyte, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
お知らせ • Sep 07Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. Mr. Soleymannezhad will lead global product development and marketing strategy for MaxCyte's bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and manufacturing using transient expression to produce complex proteins, vaccines and biologics at scale. Mr. Soleymannezhad brings almost 20 years of technical, sales and marketing expertise in biomanufacturing, bioprocessing and bioanalysis to his new role. Most recently, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience overseeing a team of 140 employees across four global manufacturing, development, and commercial sites. During his tenure at Tosoh, Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing Americas and served on the board of Semba Biosciences. Mr. Soleymannezhad received a Master of Business Administration in finance from Jones Graduate School of Business at Rice University in Texas after completing his Master and Bachelor of Chemical Engineering at University of Western Ontario's Faculty of Engineering in Canada.
New Risk • Aug 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years).
分析記事 • Aug 12Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Aug 10Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: US$0.10 loss per share (further deteriorated from US$0.081 loss in 2Q 2022). Revenue: US$9.04m (down 5.9% from 2Q 2022). Net loss: US$10.5m (loss widened 27% from 2Q 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 4.2%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects core revenue to be comparable to 2022 and Strategic Platform License program-related revenue expectations remain unchanged at approximately $6 million.
お知らせ • Jul 14MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023MaxCyte, Inc. announced that they will report Q2, 2023 results at 4:30 PM, GMT Standard Time on Aug 09, 2023
Recent Insider Transactions Derivative • Jul 13Founder notifies of intention to sell stockDouglas Doerfler intends to sell 90k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of July. If the sale is conducted around the recent share price of UK£3.61, it would amount to UK£325k. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jun 29Independent Non-Executive Director notifies of intention to sell stockJohn Johnston intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of June. If the sale is conducted around the recent share price of UK£3.68, it would amount to UK£92k. Since March 2023, John has owned 120.58k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jun 17Founder exercised options and sold UK£173k worth of stockOn the 14th of June, Douglas Doerfler exercised 44k options at a strike price of around UK£0.032 and sold these shares for an average price of UK£3.97 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • May 17Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$54.2m to US$48.3m. Forecast losses increased from -US$0.322 to -US$0.33 per share. Life Sciences industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target down from UK£9.67 to UK£8.52. Share price fell 20% to UK£3.05 over the past week.
分析記事 • May 15MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%Market forces rained on the parade of MaxCyte, Inc. ( LON:MXCT ) shareholders today, when the analysts downgraded their...
分析記事 • May 14Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%The MaxCyte, Inc. ( LON:MXCT ) share price has fared very poorly over the last month, falling by a substantial 28%. The...
Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.04 loss in 1Q 2022). Revenue: US$8.58m (down 26% from 1Q 2022). Net loss: US$10.9m (loss widened 168% from 1Q 2022). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
お知らせ • May 11MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects total revenue to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and Strategic Platform License (“SPL”) program-related revenue expectations remaining the same at approximately $6 million for the year.
分析記事 • Apr 27We Think MaxCyte (LON:MXCT) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Board Change • Apr 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Member of Scientific Advisory Board Marcela Maus was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Apr 01Key Executive recently bought UK£280k worth of stockOn the 29th of March, Richard Douglas bought around 80k shares on-market at roughly UK£3.51 per share. This transaction increased Richard's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.
Reported Earnings • Mar 16Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)Full year 2022 results: US$0.23 loss per share (further deteriorated from US$0.21 loss in FY 2021). Revenue: US$44.3m (up 31% from FY 2021). Net loss: US$23.6m (loss widened 24% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings.
Recent Insider Transactions Derivative • Feb 05Founder exercised options and sold UK£139k worth of stockOn the 2nd of February, Douglas Doerfler exercised 30k options at a strike price of around UK£0.033 and sold these shares for an average price of UK£4.66 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£996k more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Feb 02MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023MaxCyte, Inc. announced that they will report Q4, 2022 results at 4:30 PM, GMT Standard Time on Mar 15, 2023
Recent Insider Transactions Derivative • Jan 07Founder exercised options and sold UK£127k worth of stockOn the 5th of January, Douglas Doerfler exercised 30k options at a strike price of around UK£0.034 and sold these shares for an average price of UK£4.27 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£642k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Dec 07Insider exercised options and sold UK£113k worth of stockOn the 5th of December, Thomas Ross exercised 29k options at a strike price of around UK£0.89 and sold these shares for an average price of UK£4.77 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£415k more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Nov 20Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$0.29 to -US$0.26 per share. Revenue forecast steady at US$44.7m. Life Sciences industry in the United Kingdom expected to see average net income growth of 24% next year. Consensus price target broadly unchanged at UK£10.12. Share price rose 3.5% to UK£5.85 over the past week.
Recent Insider Transactions Derivative • Nov 04Insider exercised options and sold UK£154k worth of stockOn the 2nd of November, Thomas Ross exercised 29k options at a strike price of around UK£0.73 and sold these shares for an average price of UK£6.03 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£6.8m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Oct 13Insider exercised options and sold UK£147k worth of stockOn the 11th of October, Thomas Ross exercised 29k options at a strike price of around UK£0.76 and sold these shares for an average price of UK£5.81 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£6.6m more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$43.6m to US$44.7m. Forecast EPS reduced from -US$0.25 to -US$0.28 per share. Life Sciences industry in the United Kingdom expected to see average net income growth of 24% next year. Consensus price target up from UK£9.76 to UK£10.18. Share price rose 6.2% to UK£4.73 over the past week.
Reported Earnings • Aug 11Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.081 loss per share (down from US$0.052 loss in 2Q 2021). Revenue: US$9.61m (up 35% from 2Q 2021). Net loss: US$8.26m (loss widened 87% from 2Q 2021). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 25% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.04 loss per share (up from US$0.088 loss in 1Q 2021). Revenue: US$11.6m (up 78% from 1Q 2021). Net loss: US$4.07m (loss narrowed 43% from 1Q 2021). Revenue exceeded analyst estimates by 36%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Over the next year, revenue is forecast to grow 17%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
